Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?

Chia Hao Chang; Chih Hsin Lee; Jann Yuan Wang

doi:10.1200/JCO.2016.68.5842

Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?

Chia Hao Chang, Chih Hsin Lee, Jann Yuan Wang

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1374
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	35
Issue number	12
DOIs	https://doi.org/10.1200/JCO.2016.68.5842
Publication status	Published - Apr 20 2017

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2016.68.5842

Cite this

@article{9df17019506343d7a5021c65e9c83525,

title = "Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?",

author = "Chang, {Chia Hao} and Lee, {Chih Hsin} and Wang, {Jann Yuan}",

year = "2017",

month = apr,

day = "20",

doi = "10.1200/JCO.2016.68.5842",

language = "English",

volume = "35",

pages = "1374",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "12",

}

TY - JOUR

T1 - Gefitinib or erlotinib for previously treated lung adenocarcinoma

T2 - Which is superior?

AU - Chang, Chia Hao

AU - Lee, Chih Hsin

AU - Wang, Jann Yuan

PY - 2017/4/20

Y1 - 2017/4/20

UR - http://www.scopus.com/inward/record.url?scp=85017648983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017648983&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.68.5842

DO - 10.1200/JCO.2016.68.5842

M3 - Letter

AN - SCOPUS:85017648983

SN - 0732-183X

VL - 35

SP - 1374

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 12

ER -

Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this